Recent Research Publications

1. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Li, D., Sharp, L.L., Torigian, D.A., O’Dwyer, P.J., and R.H Vonderheide. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612-16. PMCID: PMC3406187.
2. Rhim, A.D, Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McCallister, F., Reichert, M., Beatty, G.L., Rustgi, A.K.., Vonderheide, R.H., Leach, S.D., and B.Z. Stanger. 2012. EMT and dissemination precede pancreatic tumor formation. Cell. 148:349-61. PMCID: PMC3266542.
3. Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., and R.H. Vonderheide. 2012. Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21:822-35. PMCID: PMC3575028. 
4. Maus, M.V., Haas, A.R., Beatty, G.L., Albelda, S.M., Levine, B.L., Liu, X., Zhao, Y., Kalos, M., and C.H. June. 2013. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 1:26-31. PMCID: PMC3888798.
5. Beatty, G.L., Torigian, D.A., Chiorean, E.G., Saboury, B., Brothers, A., Alavi, A., Troxel, A.B., Sun, W., Teitelbaum, U.R., Vonderheide, R.H., and P.J. O'Dwyer. 2013. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 19:6286-95. PMCID: PMC3834036.
6. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., Kalos, M., and C.H. June. 2014. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunology Research. 2:112-120. PMCID: PMC3932715.
7. Beatty, G.L., Winograd, R., Evans, R.A., Long, K.B., Luque, S.L., Lee, J.W., Gladney, W.L., Guirnalda, P.D., and R.H. Vonderheide. 2015. Productive T cell immunity against pancreatic carcinoma in mice is regulated by Ly6Clow F4/80+ extratumoral macrophages. Gastroenterology. 149:201 PMCID: PMC4478138. 
8. Long, K.B., Gladney, W.L., Tooker, G.M., Graham, K., Fraietta, J.A., and G.L. Beatty. 2016. IFN-gamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discovery. 6:400-413. PMCID: PMC4843521.
9. Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F.M., Flannagan, K., Rhim, A.D., Simeone, D.M., Beatty G.L. and M. Pasca di Magliano. 2017. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 66: 124-136. PMID: 27402485. 
10. Kalbasi, A., Komar, C.A., Tooker, G.M., Liu, M., Lee, J.W., Gladney, W.L., and G.L. Beatty. 2017. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res. 23:137-148. PMCID: PMC5195913. 
11. Beatty, G.L., O’Dwyer, P.J., Clark, J., Shi, J.G., Bowman, K.J., Scherle, P.A., Newton, R.C., Schaub, R., Maleski, J., Leopold, L., and T.F. Gajewski. 2017. First-in-human phase 1 study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. In press.
12. Long, K.B., Tooker, G., Tooker, E., Luque, S.L., Lee, J.W., Pan, X., and G.L. Beatty. 2017 IL-6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Mol Cancer Ther. In press.